<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135015</url>
  </required_header>
  <id_info>
    <org_study_id>GIL-1665</org_study_id>
    <nct_id>NCT03135015</nct_id>
  </id_info>
  <brief_title>Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans</brief_title>
  <official_title>Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Housey Healthcare ULC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glycemic Index Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Housey Healthcare ULC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After
      a meal, carbohydrates are broken down into glucose (blood sugar) which is absorbed from the
      intestine into the blood leading to a rise in glucose which triggers the secretion of
      insulin. Insulin binds to cells in the liver, muscle and fat, triggering them to take up
      glucose and bring the blood glucose level back to normal.

      A high blood sugar level is known as diabetes. The most common form of diabetes, type 2
      diabetes, is caused by insulin resistance; that is, a reduced ability of insulin to stimulate
      glucose uptake into cells. The body compensates for insulin resistance by making more
      insulin; type 2 diabetes occurs when the pancreas can no longer make enough insulin to
      control blood glucose. The high blood glucose and insulin levels lead to long-term
      complications such as heart attacks, kidney failure, reduced sensation and poor circulation
      in the feet and legs. Reducing blood glucose levels with oral medications and insulin reduces
      risk of diabetic complications. There are several types of oral medications available for
      treating diabetes; however, they do not always control blood glucose adequately. In addition,
      these drugs have complications and are not used to treat insulin resistance and prediabetes -
      a condition when blood glucose is higher than normal but not high enough to be classified as
      diabetes. Prediabetes often progresses to diabetes over a period of months or years.
      Effective and safe treatments for prediabetes could prevent or delay the onset of diabetes.

      Axulin is a natural health product consisting of a mixture of extracts - derived from herbs
      and vegetables present in normal diets - which has been shown in cell culture and in animal
      studies to increase the ability of insulin to stimulate glucose uptake into cells. The active
      ingredient in Axulin is a botanical extract designated HP-211. Thus, HP-211 may reduce the
      blood glucose and insulin levels of subjects without diabetes after eating. HP-211 may also
      reduce glucose and insulin responses to a larger extent in insulin-resistant as compared to
      insulin-sensitive subjects.

      Subjects will take 0g, 2g, or 4g of capsules or tablets in the morning after an overnight
      fast; 40 minutes later they will consume 75g glucose dissolved in 300ml water. Blood glucose,
      insulin and fats will be measured before and for 2 hours after the glucose drink.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consumption of a meal, pancreatic secretions of various digestive enzymes results in
      the breakdown of carbohydrates into monosaccharides including glucose. These sugars are
      subsequently absorbed through the intestinal lumen, resulting in an increased plasma glucose
      concentration. In response to high glucose levels, pancreatic beta-cells are stimulated to
      release the hormone insulin which circulates through the bloodstream and binds to
      insulin-responsive cells including adipocytes (fat tissue), myocytes (muscle tissue), and
      hepatocytes (liver). The resulting insulin-mediated signaling cascade initiates intracellular
      glucose uptake within peripheral tissues leading to a corresponding decrease in circulating
      plasma glucose.

      In insulin responsive cells glucose uptake stimulation begins after the binding of insulin to
      Insulin Receptors (IR), which are found on the membrane surface of cells in insulin
      responsive tissues such as fat, muscle and liver. The IR consists of an extracellular domain
      which binds to insulin, and an intracellular domain that has a protein tyrosine kinase
      activity. The binding of Insulin to the IR initiates a series of auto-phosphorylation events
      within the protein kinase domain that permit interaction and phosphorylation of downstream
      signaling proteins in the cell that mediate the cellular response to insulin. The resulting
      signaling complex includes proteins in the Insulin Receptor Substrate (IRS) family known as
      IRS-1 and IRS-2. These key targets of the insulin signaling pathway link IR activation to
      downstream signaling cascades that mediate intracellular processes including GLUT4-mediated
      glucose uptake.

      Prediabetes and Type II diabetes involve an impaired post-receptor response to insulin that
      hinders the glucose uptake response after meal consumption. Chronic hyperglycemia and the
      resulting compensatory hyperinsulinemia promote a cohort of acute and chronic sequelae
      including cardiovascular disease, liver complications, central nervous system degeneration
      and hyperglycemic osmotic stress. Axulin is a natural health product consisting of a mixture
      of extracts from herbs and vegetables present in normal diets which was identified by
      screening more than 100,000 compounds and extracts in a patented cell-culture based assay
      system targeting the IRS proteins. In vitro, Axulin's active ingredient, HP-211, has marked
      effects on the IRS-2 branch of the insulin signaling cascade to enhance downstream insulin
      signaling. HP-211 has been shown in animal models to increase glucose uptake in peripheral
      tissues and decrease circulating blood glucose and triglyceride concentrations. Regular
      supplementation of the diet with Axulin would be expected to reduce the incidence of
      associated prediabetic and diabetic complications, resulting in an increased quality of life
      for patients without resorting to current anti-diabetic prescription drugs such as metformin
      and others that may have substantial unwanted side effects in patients.

      HYPOTHESES Axulin will reduce postprandial glucose and insulin responses in a dose-dependent
      fashion in healthy subjects without diabetes. The reduction in glucose and insulin will be
      relatively greater in insulin-resistant than insulin-sensitive subjects.

      Subjects will take 0g, 2g, or 4g of capsules or tablets in the morning after an overnight
      fast; 40 minutes later they will consume 75g glucose dissolved in 300ml water. Blood glucose,
      insulin and triglycerides will be measured fasting and at intervals for 2 hours after the
      glucose drink.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Actual">June 21, 2017</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each participant in 2 participant groups will undergo each of 6 treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Capsule treatments will be fully blinded. Tablet treatments will be open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Percentage change in the incremental area under the glucose response curve (AUC) after 75g glucose for capsules and tablets containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Area Under The Curve (AUC) 0-2 Hours</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Incremental area under the blood glucose response curve (AUC) is the AUC below the glucose response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin Area Under The Curve (AUC) 0-2 Hours</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Incremental area under the serum insulin response curve (AUC) is the AUC below the insulin response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Area Under The Curve (AUC) for Serum Insulin 0-2 Hours</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Percentage change in the incremental area under the insulin response curve (AUC) after 75g glucose for the capsules containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic Index</measure>
    <time_frame>Baseline and 30 minutes</time_frame>
    <description>Insulinogenic Index is an index of the ability of a change in blood glucose to stimulate an increase in serum insulin. It is a unitless measure with higher numbers indicating improved beta cell function. It is calculated by dividing the change in serum insulin between 0 and 30 minutes by the change in blood glucose between 0 and 30 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Insulin Sensitivity Index</measure>
    <time_frame>0, 30, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Matsuda Insulin Sensitivity Index is an index of whole body insulin sensitivity derived from glucose and insulin responses after a 75g Oral Glucose Tolerance Test (OGTT). It is calculated by 10000 divided by the square root of (FG*FI*MG*MI) where FG is fasting glucose, FI is fasting insulin, MG is the mean AUC for blood glucose at 0, 30, 60, 90 and 120 minutes and MI is the mean AUC for serum insulin at 0, 30, 60, 90 and 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISSI-2 Index of Beta-cell Function</measure>
    <time_frame>0, 30, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Insulin Secretion-Sensitivity Index-2 (ISSI-2) is an index of β-cell function with insulin secretion adjusted for whole body insulin sensitivity. It is calculated by the total area under the curve for serum insulin divided by the area under the curve for blood glucose, and that result times the Matsuda insulin sensitivity index (defined above).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of Axulin in Lean vs. Overweight Participants</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Percentage change in blood glucose area under the curve (AUC) in lean participants compared to overweight participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of Capsules vs. Tablets</measure>
    <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
    <description>Percentage change in blood glucose area under the curve (AUC) elicited by capsules compared to the same dose of tablets.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Insulin Resistance, Diabetes</condition>
  <arm_group>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with BMI &gt;18.5 and &lt;25.0kg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants with BMI ≥25.0 and &lt;35.0kg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>250ml water with 16 x 250mg placebo capsules</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2g capsules</intervention_name>
    <description>250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4g capsules</intervention_name>
    <description>250ml water with 16 x 250mg capsules containing Axulin powder</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water Control</intervention_name>
    <description>250ml water</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2g tablets</intervention_name>
    <description>250ml water with 2 x 1g tablets containing Axulin powder</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>4g tablets</intervention_name>
    <description>250ml water with 4 x 1g tablets containing Axulin powder</description>
    <arm_group_label>Lean Participants</arm_group_label>
    <arm_group_label>Overweight/Obese Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants taking stable doses (for at least 4 weeks of signing the consent form) of
             the birth control pill, thyroxin replacement therapy, statins, fibrates, cholesterol
             absorption inhibitors, anti-hypertensive medications, asprin, non-steroidal
             anti-inflammatories and/or mild anxiolytics or sedatives can be included.

        Exclusion Criteria:

          -  Fasting serum glucose &gt;6.9mmol/L (124mg/dL)

          -  HbA1c &gt;6.4%

          -  Fasting serum triglycerides &gt;4.5 mmol/L (399 mg/dL)

          -  Fasting LDL cholesterol &gt;4.99 mmol/L (192 mg/dL)

          -  Blood pressure &gt;149 systolic or &gt;89 diastolic

          -  Serum creatinine, or aspartate- or alanine transaminases &gt;1.2 times upper limit of
             normal

          -  White cell count, red blood cell count, hemoglobin or hematocrit outside normal range

          -  Hospitalization for surgery or a medical condition within 3 months of signing the
             consent form

          -  Use of any drug to treat diabetes

          -  Use of medications other than those listed above or the presence of any condition
             which might, in the opinion of Dr. Wolever, either: 1) make participation dangerous to
             the subject or to others, or 2) affect the results

          -  Allergy or sensitivity to tarragon, chromium, escarole, lettuce, microcrystalline
             cellulose, inulin, food colouring (FD&amp;C Yellow#5 and Blue#1) or vegetable-based
             capsules (silicon dioxide, titanium dioxide, hydroxypropylmethylcellulose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas MS Wolever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glycemic Index Laboratories, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycemic Index Laboratories, Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>April 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2020</results_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03135015/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 26-APRIL-2017 to 24-MAY-2017 at GI Labs (20 Victoria St., Toronto ON, M5C 2N8).</recruitment_details>
      <pre_assignment_details>A screening visit was conducted to ensure each participant met inclusion/exclusion criteria for the study. Participants that qualified for the study were separated into either the lean or the overweight group as per protocol (11 subjects/arm).Participants were assigned to a randomization schedule in order of enrollment within each group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lean Participants</title>
          <description>Participants with BMI &gt;18.5 and &lt;25.0kg/m². All participants received each of the 6 interventions in a randomized manner.</description>
        </group>
        <group group_id="P2">
          <title>Overweight/Obese Participants</title>
          <description>Participants with BMI ≥25.0 and &lt;35.0kg/m². All participants received each of the 6 interventions in a randomized manner.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Water Control</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo Capsules</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2g Capsules</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4g Capsules</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2g Tablets</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4g Tablets</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis of baseline characteristics includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Lean Participants</title>
          <description>Participants with BMI &gt;18.5 and &lt;25.0kg/m². All participants received each of the 6 interventions in a randomized manner.</description>
        </group>
        <group group_id="B2">
          <title>Overweight/Obese Participants</title>
          <description>Participants with BMI ≥25.0 and &lt;35.0kg/m². All participants received each of the 6 interventions in a randomized manner.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="9.1"/>
                    <measurement group_id="B2" value="45" spread="13"/>
                    <measurement group_id="B3" value="39.5" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" spread="1.7"/>
                    <measurement group_id="B2" value="28.5" spread="2.7"/>
                    <measurement group_id="B3" value="25.4" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours</title>
        <description>Percentage change in the incremental area under the glucose response curve (AUC) after 75g glucose for capsules and tablets containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of primary outcome data is based on all randomized subjects who received this intervention and for whom primary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours</title>
          <description>Percentage change in the incremental area under the glucose response curve (AUC) after 75g glucose for capsules and tablets containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
          <population>The analysis of primary outcome data is based on all randomized subjects who received this intervention and for whom primary outcome data is known. There is no missing value imputation.</population>
          <units>mmol x min/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.09" spread="27.6405"/>
                    <measurement group_id="O2" value="258.66" spread="27.6405"/>
                    <measurement group_id="O3" value="248.63" spread="27.6405"/>
                    <measurement group_id="O4" value="274.13" spread="27.1449"/>
                    <measurement group_id="O5" value="325.73" spread="0.7879"/>
                    <measurement group_id="O6" value="306.19" spread="52.3273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1146</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-14.09</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0519</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-17.42</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-8.95</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Glucose Area Under The Curve (AUC) 0-2 Hours</title>
        <description>Incremental area under the blood glucose response curve (AUC) is the AUC below the glucose response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Area Under The Curve (AUC) 0-2 Hours</title>
          <description>Incremental area under the blood glucose response curve (AUC) is the AUC below the glucose response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>mmol x min/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.09" spread="27.6405"/>
                    <measurement group_id="O2" value="258.66" spread="27.6405"/>
                    <measurement group_id="O3" value="248.63" spread="27.6405"/>
                    <measurement group_id="O4" value="274.13" spread="27.1449"/>
                    <measurement group_id="O5" value="325.73" spread="0.7879"/>
                    <measurement group_id="O6" value="306.19" spread="52.3273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1146</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0519</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Insulin Area Under The Curve (AUC) 0-2 Hours</title>
        <description>Incremental area under the serum insulin response curve (AUC) is the AUC below the insulin response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Insulin Area Under The Curve (AUC) 0-2 Hours</title>
          <description>Incremental area under the serum insulin response curve (AUC) is the AUC below the insulin response curve above the fasting level; area below fasting is ignored. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done.</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>uU x min/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4379.31" spread="625.35"/>
                    <measurement group_id="O2" value="4005.61" spread="634.61"/>
                    <measurement group_id="O3" value="4787.44" spread="634.61"/>
                    <measurement group_id="O4" value="4135.18" spread="493.30"/>
                    <measurement group_id="O5" value="4452.09" spread="461.79"/>
                    <measurement group_id="O6" value="4381.71" spread="545.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5827</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5485</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Area Under The Curve (AUC) for Serum Insulin 0-2 Hours</title>
        <description>Percentage change in the incremental area under the insulin response curve (AUC) after 75g glucose for the capsules containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Area Under The Curve (AUC) for Serum Insulin 0-2 Hours</title>
          <description>Percentage change in the incremental area under the insulin response curve (AUC) after 75g glucose for the capsules containing Axulin powder relative to the water control. Incremental AUC is the AUC below the curve above the fasting level; area below fasting is ignored. Percentage change will be calculated as 100 x (A-P)/P where A and P are the mean AUC's after Axulin and water control treatments, respectively. The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons. The code will be broken after this analysis has been done. The percentage changes will be considered to be significant if the difference in mean AUC is significant.</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>uU x min/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4379.31" spread="625.35"/>
                    <measurement group_id="O2" value="4005.61" spread="634.61"/>
                    <measurement group_id="O3" value="4787.44" spread="634.61"/>
                    <measurement group_id="O4" value="4135.18" spread="493.30"/>
                    <measurement group_id="O5" value="4452.09" spread="461.79"/>
                    <measurement group_id="O6" value="4381.71" spread="545.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5827</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-8.53</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The blinded AUC results for the 6 treatments will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 6 coded treatments, differences between individual means will be assessed using Tukey’s test to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5485</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>9.32</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulinogenic Index</title>
        <description>Insulinogenic Index is an index of the ability of a change in blood glucose to stimulate an increase in serum insulin. It is a unitless measure with higher numbers indicating improved beta cell function. It is calculated by dividing the change in serum insulin between 0 and 30 minutes by the change in blood glucose between 0 and 30 minutes.</description>
        <time_frame>Baseline and 30 minutes</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index</title>
          <description>Insulinogenic Index is an index of the ability of a change in blood glucose to stimulate an increase in serum insulin. It is a unitless measure with higher numbers indicating improved beta cell function. It is calculated by dividing the change in serum insulin between 0 and 30 minutes by the change in blood glucose between 0 and 30 minutes.</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>Insulinogenic Index</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.462" spread="2.276"/>
                    <measurement group_id="O2" value="15.540" spread="2.769"/>
                    <measurement group_id="O3" value="17.436" spread="2.879"/>
                    <measurement group_id="O4" value="15.059" spread="3.401"/>
                    <measurement group_id="O5" value="13.785" spread="2.772"/>
                    <measurement group_id="O6" value="13.580" spread="2.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1234</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0331</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Insulin Sensitivity Index</title>
        <description>Matsuda Insulin Sensitivity Index is an index of whole body insulin sensitivity derived from glucose and insulin responses after a 75g Oral Glucose Tolerance Test (OGTT). It is calculated by 10000 divided by the square root of (FG*FI*MG*MI) where FG is fasting glucose, FI is fasting insulin, MG is the mean AUC for blood glucose at 0, 30, 60, 90 and 120 minutes and MI is the mean AUC for serum insulin at 0, 30, 60, 90 and 120 minutes.</description>
        <time_frame>0, 30, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Insulin Sensitivity Index</title>
          <description>Matsuda Insulin Sensitivity Index is an index of whole body insulin sensitivity derived from glucose and insulin responses after a 75g Oral Glucose Tolerance Test (OGTT). It is calculated by 10000 divided by the square root of (FG*FI*MG*MI) where FG is fasting glucose, FI is fasting insulin, MG is the mean AUC for blood glucose at 0, 30, 60, 90 and 120 minutes and MI is the mean AUC for serum insulin at 0, 30, 60, 90 and 120 minutes.</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>Matsuda Insulin Sensitivity Index</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.116" spread="25.116"/>
                    <measurement group_id="O2" value="165.289" spread="20.926"/>
                    <measurement group_id="O3" value="155.64" spread="15.775"/>
                    <measurement group_id="O4" value="186.468" spread="23.788"/>
                    <measurement group_id="O5" value="167.004" spread="15.441"/>
                    <measurement group_id="O6" value="189.457" spread="17.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0500</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0568</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ISSI-2 Index of Beta-cell Function</title>
        <description>Insulin Secretion-Sensitivity Index-2 (ISSI-2) is an index of β-cell function with insulin secretion adjusted for whole body insulin sensitivity. It is calculated by the total area under the curve for serum insulin divided by the area under the curve for blood glucose, and that result times the Matsuda insulin sensitivity index (defined above).</description>
        <time_frame>0, 30, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>ISSI-2 Index of Beta-cell Function</title>
          <description>Insulin Secretion-Sensitivity Index-2 (ISSI-2) is an index of β-cell function with insulin secretion adjusted for whole body insulin sensitivity. It is calculated by the total area under the curve for serum insulin divided by the area under the curve for blood glucose, and that result times the Matsuda insulin sensitivity index (defined above).</description>
          <population>The analysis of secondary outcome data is based on all randomized subjects who received this intervention and for whom secondary outcome data is known. There is no missing value imputation.</population>
          <units>Insulin Secretion-Sensitivity Index-2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816.475" spread="50.412"/>
                    <measurement group_id="O2" value="705.232" spread="49.158"/>
                    <measurement group_id="O3" value="773.354" spread="60.735"/>
                    <measurement group_id="O4" value="727.130" spread="43.000"/>
                    <measurement group_id="O5" value="783.328" spread="46.155"/>
                    <measurement group_id="O6" value="880.822" spread="60.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0509</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect of Axulin in Lean vs. Overweight Participants</title>
        <description>Percentage change in blood glucose area under the curve (AUC) in lean participants compared to overweight participants.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>Water Control, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O3">
            <title>2g Capsules, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O4">
            <title>2g Capsules, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>4g Capsules, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Capsules, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O7">
            <title>2g Tablets, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O8">
            <title>2g Tablets, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O9">
            <title>4g Tablets, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O10">
            <title>4g Tablets, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O11">
            <title>Placebo Capsules, Lean Participants</title>
            <description>Lean Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O12">
            <title>Placebo Capsules, Overweight Participants</title>
            <description>Overweight Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Axulin in Lean vs. Overweight Participants</title>
          <description>Percentage change in blood glucose area under the curve (AUC) in lean participants compared to overweight participants.</description>
          <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol x min/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.704" spread="26.343"/>
                    <measurement group_id="O2" value="264.474" spread="31.965"/>
                    <measurement group_id="O3" value="286.425" spread="30.944"/>
                    <measurement group_id="O4" value="230.891" spread="35.892"/>
                    <measurement group_id="O5" value="291.083" spread="50.563"/>
                    <measurement group_id="O6" value="206.168" spread="32.895"/>
                    <measurement group_id="O7" value="326.517" spread="34.054"/>
                    <measurement group_id="O8" value="324.941" spread="48.047"/>
                    <measurement group_id="O9" value="358.513" spread="38.841"/>
                    <measurement group_id="O10" value="253.858" spread="33.223"/>
                    <measurement group_id="O11" value="290.325" spread="54.912"/>
                    <measurement group_id="O12" value="243.699" spread="39.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8444</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9681</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.1022</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.3738</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.550</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.362</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.387</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.738</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.463</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.929</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.282</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect of Capsules vs. Tablets</title>
        <description>Percentage change in blood glucose area under the curve (AUC) elicited by capsules compared to the same dose of tablets.</description>
        <time_frame>0, 15, 30, 45, 60, 90, and 120 minutes post-dose</time_frame>
        <population>The analysis of the outcome measure is based on all randomized participants who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O5">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Capsules vs. Tablets</title>
          <description>Percentage change in blood glucose area under the curve (AUC) elicited by capsules compared to the same dose of tablets.</description>
          <population>The analysis of the outcome measure is based on all randomized participants who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol x min/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.428" spread="22.296"/>
                    <measurement group_id="O2" value="255.881" spread="24.383"/>
                    <measurement group_id="O3" value="325.650" spread="29.800"/>
                    <measurement group_id="O4" value="244.380" spread="29.859"/>
                    <measurement group_id="O5" value="300.953" spread="27.350"/>
                    <measurement group_id="O6" value="264.681" spread="32.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1684</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.604</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.722</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>12.755</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.489</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.293</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.664</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.526</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.813</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Percentage Change from Control</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Blood Glucose Change From Baseline in the Water Control Compared to the Placebo Capsules at 90 Minutes for All Participants</title>
        <description>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the water control and the placebo capsule treatments will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
        <time_frame>From Baseline at 90 minutes</time_frame>
        <population>The analysis of the outcome measure is based on all randomized participants who received this intervention and for whom the outcome data is known. The comparison is between the water control and the placebo capsules only. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Change From Baseline in the Water Control Compared to the Placebo Capsules at 90 Minutes for All Participants</title>
          <description>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the water control and the placebo capsule treatments will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
          <population>The analysis of the outcome measure is based on all randomized participants who received this intervention and for whom the outcome data is known. The comparison is between the water control and the placebo capsules only. There is no missing value imputation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.475" spread="0.2736"/>
                    <measurement group_id="O2" value="1.953" spread="0.2969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0374</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-21.09</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>60-Minute Blood Glucose Area Under the Curve (AUC)</title>
        <description>Incremental area under the blood glucose response curve (AUC) will be computed using the values recorded at 60 minutes and beyond. The blinded AUC results for the Axulin capsule treatments and the water control will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 3 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons.</description>
        <time_frame>1-2 hours post-dose</time_frame>
        <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>60-Minute Blood Glucose Area Under the Curve (AUC)</title>
          <description>Incremental area under the blood glucose response curve (AUC) will be computed using the values recorded at 60 minutes and beyond. The blinded AUC results for the Axulin capsule treatments and the water control will be subjected to repeated measures analysis of variance (ANOVA) examining for the main effects of treatment and participant-group, and treatment*group interaction. After demonstration of significant heterogeneity among the 3 coded treatments, differences between individual means will be assessed using Tukey's test to adjust for multiple comparisons.</description>
          <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol x min/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.300" spread="13.533"/>
                    <measurement group_id="O2" value="105.566" spread="11.417"/>
                    <measurement group_id="O3" value="104.450" spread="15.392"/>
                    <measurement group_id="O4" value="118.316" spread="15.907"/>
                    <measurement group_id="O5" value="153.618" spread="18.640"/>
                    <measurement group_id="O6" value="135.475" spread="16.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0098</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-24.22</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0391</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-25.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in All Participants</title>
        <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
        <time_frame>From Baseline at 90 and 120 minutes</time_frame>
        <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in All Participants</title>
          <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
          <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>90-Minute Blood Glucose CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.475" spread="0.274"/>
                    <measurement group_id="O2" value="1.577" spread="0.252"/>
                    <measurement group_id="O3" value="1.653" spread="0.291"/>
                    <measurement group_id="O4" value="1.953" spread=".297"/>
                    <measurement group_id="O5" value="2.338" spread=".378"/>
                    <measurement group_id="O6" value="2.089" spread=".289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120-Minute Blood Glucose CFB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.469" spread="0.245"/>
                    <measurement group_id="O2" value="0.686" spread="0.249"/>
                    <measurement group_id="O3" value="0.790" spread="0.228"/>
                    <measurement group_id="O4" value="1.032" spread=".258"/>
                    <measurement group_id="O5" value="1.453" spread=".256"/>
                    <measurement group_id="O6" value="1.507" spread=".313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-36.28</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-33.21</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-53.27</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-46.19</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in Lean Participants</title>
        <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes for the Lean Participants. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
        <time_frame>From Baseline at 90 and 120 minutes</time_frame>
        <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>Lean Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>Lean Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>Lean Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>Lean Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>Lean Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>Lean Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in Lean Participants</title>
          <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes for the Lean Participants. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
          <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>90-Minute Blood Glucose CFB in Lean Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.902" spread="0.238"/>
                    <measurement group_id="O2" value="1.992" spread="0.379"/>
                    <measurement group_id="O3" value="2.022" spread="0.505"/>
                    <measurement group_id="O4" value="2.546" spread=".457"/>
                    <measurement group_id="O5" value="2.542" spread=".366"/>
                    <measurement group_id="O6" value="2.818" spread=".426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120-Minute Blood Glucose CFB in Lean Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.232" spread="0.206"/>
                    <measurement group_id="O2" value="1.340" spread="0.361"/>
                    <measurement group_id="O3" value="1.299" spread="0.366"/>
                    <measurement group_id="O4" value="1.710" spread=".438"/>
                    <measurement group_id="O5" value="1.857" spread=".359"/>
                    <measurement group_id="O6" value="2.479" spread=".354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0788</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-31.36</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0887</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-30.32</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0266</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-39.96</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0455</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-41.80</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in Overweight Participants</title>
        <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes for the Obese/Overweight Participants. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
        <time_frame>From Baseline at 90 and 120 minutes</time_frame>
        <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>Overweight Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>Overweight Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>Overweight Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>Overweight Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>Overweight Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>Overweight Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Glucose Change From Baseline at 90 and 120 Minutes in Overweight Participants</title>
          <description>Change from baseline (CFB) in blood glucose will be computed at 90 and 120 minutes for the Obese/Overweight Participants. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
          <population>Arms/Groups are provided as appropriate. The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>90-Min Blood Glucose CFB, Overweight Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.126" spread="0.441"/>
                    <measurement group_id="O2" value="1.237" spread="0.316"/>
                    <measurement group_id="O3" value="1.351" spread="0.326"/>
                    <measurement group_id="O4" value="1.469" spread=".340"/>
                    <measurement group_id="O5" value="2.171" spread=".632"/>
                    <measurement group_id="O6" value="1.491" spread=".301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120-Min Blood Glucose CFB, Overweight Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.844" spread="0.305"/>
                    <measurement group_id="O2" value="0.151" spread="0.257"/>
                    <measurement group_id="O3" value="0.373" spread="0.230"/>
                    <measurement group_id="O4" value=".477" spread=".190"/>
                    <measurement group_id="O5" value="1.122" spread=".342"/>
                    <measurement group_id="O6" value=".711" spread=".338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0261</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-41.82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0391</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-36.45</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0372</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-82.11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in blood glucose will be computed at 120 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1631</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-55.81</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Insulin Change From Baseline at 90 Minutes in All Participants</title>
        <description>Change from baseline (CFB) in insulin will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
        <time_frame>From Baseline at 90 minutes</time_frame>
        <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Water Control</title>
            <description>All Participants randomized to receive 250ml water.</description>
          </group>
          <group group_id="O2">
            <title>2g Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>4g Capsules</title>
            <description>All Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Capsules</title>
            <description>All Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
          </group>
          <group group_id="O5">
            <title>2g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
          </group>
          <group group_id="O6">
            <title>4g Tablets</title>
            <description>All Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Change From Baseline at 90 Minutes in All Participants</title>
          <description>Change from baseline (CFB) in insulin will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</description>
          <population>The analysis of other outcome measures is based on all randomized subjects who received this intervention and for whom the outcome data is known. There is no missing value imputation.</population>
          <units>uU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.345" spread="10.046"/>
                    <measurement group_id="O2" value="25.896" spread="4.174"/>
                    <measurement group_id="O3" value="38.851" spread="12.260"/>
                    <measurement group_id="O4" value="38.179" spread="6.175"/>
                    <measurement group_id="O5" value="37.152" spread="5.383"/>
                    <measurement group_id="O6" value="38.388" spread="7.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in insulin will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0303</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-46.43</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline (CFB) in insulin will be computed at 90 minutes. The CFB results for the capsule treatments and the water control will be subjected to a paired t-test examining whether the mean difference between the two sets of observations is equal to zero.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4283</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Percentage Change from Control</param_type>
            <param_value>-19.64</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored for each participant from the time informed consent was signed through study completion; April 26, 2017 - June 21, 2017, an average of 2 months.</time_frame>
      <desc>Serious classification based on the FDA regulatory definition of a serious Adverse Event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Water Control, Lean Participants</title>
          <description>Participants randomized to receive 250ml water.</description>
        </group>
        <group group_id="E2">
          <title>Water Control, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Capsules, Lean Participants</title>
          <description>Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Capsules, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water.with 16 x 250mg placebo capsules.</description>
        </group>
        <group group_id="E5">
          <title>2g Capsules, Lean Participants</title>
          <description>Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
        </group>
        <group group_id="E6">
          <title>2g Capsules, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water.with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules.</description>
        </group>
        <group group_id="E7">
          <title>4g Capsules, Lean Participants</title>
          <description>Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
        </group>
        <group group_id="E8">
          <title>4g Capsules, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water with 16 x 250mg capsules containing Axulin powder.</description>
        </group>
        <group group_id="E9">
          <title>2g Tablets, Lean Participants</title>
          <description>Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
        </group>
        <group group_id="E10">
          <title>2g Tablets, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water with 2 x 1g tablets containing Axulin powder.</description>
        </group>
        <group group_id="E11">
          <title>4g Tablets, Lean Participants</title>
          <description>Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
        </group>
        <group group_id="E12">
          <title>4g Tablets, Overweight/Obese Participants</title>
          <description>Participants randomized to receive 250ml water with 4 x 1g tablets containing Axulin powder.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Note: The dissolution time for the tablets is substantially longer (&gt;60 min) than it is for the capsules, so it would not be expected that the tablet formulation would exhibit a pharmacologic response if administered only 40 minutes before the GTT.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Project Manager</name_or_title>
      <organization>Housey Healthcare ULC</organization>
      <phone>2486637000</phone>
      <email>info@housey.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

